High Tech Pharm Valuation

Is A106190 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A106190 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: A106190 (₩15170) is trading below our estimate of fair value (₩130167.8)

Significantly Below Fair Value: A106190 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A106190?

Key metric: As A106190 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for A106190. This is calculated by dividing A106190's market cap by their current earnings.
What is A106190's PE Ratio?
PE Ratio	11.1x
Earnings	₩14.56b
Market Cap	₩161.31b

A106190 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	2x
Enterprise Value/EBITDA	7x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does A106190's PE Ratio compare to its peers?

The above table shows the PE ratio for A106190 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	25.8x
A032300 KOREA PHARMA	58.3x	n/a	₩174.5b
A023910 Daihan PharmaceuticalLtd	5x	0.9%	₩154.1b
A214390 Kyongbo Pharmaceutical	33.2x	n/a	₩177.9b
A234080 JW Lifescience	6.8x	n/a	₩180.7b
A106190 High Tech Pharm	11.1x	n/a	₩161.3b

Price-To-Earnings vs Peers: A106190 is good value based on its Price-To-Earnings Ratio (11.1x) compared to the peer average (25.8x).

Price to Earnings Ratio vs Industry

How does A106190's PE Ratio compare vs other companies in the KR Pharmaceuticals Industry?

1 Company	Price / Earnings	Estimated Growth	Market Cap
A007370 Jin Yang Pharmaceutical	2.4x	n/a	US$47.51m

No more companies available in this PE range

1 Company		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: A106190 is good value based on its Price-To-Earnings Ratio (11.1x) compared to the KR Pharmaceuticals industry average (14.2x).

Price to Earnings Ratio vs Fair Ratio

What is A106190's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A106190 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	11.1x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate A106190's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Hugel

₩3.0t

Develops and manufactures biopharmaceuticals in South Korea and internationally.

A145020

₩271,000.00

-1.8%

76.5%

J2KBIO

₩52.5b

A bio venture company, provides active ingredients for cosmetics, functional food, and household products from natural materials and microbial fermentation.

A420570

₩9,180.00

-4.8%

n/a

Ildong Pharmaceutical

₩339.7b

Develops, manufactures, and sells pharmaceutical products in South Korea.

A249420

₩12,160.00

0.08%

-29.3%